Aslan gains rights to A*STAR's RON antibody in research deal on Asia-prevalent cancers

1 September 2016

Aslan Pharmaceuticals is to develop and commercialize a new immuno-oncology antibody targeting RON (recepteur d’origine Nantais) after announcing a collaboration with Singapore’s Agency for Science, Technology and Research (A*STAR).

The Singapore-based biotech, which is focused on the development of immunotherapies and targeted agents for Asia-prevalent tumor types, has gained global rights to develop the RON antibody and intends to commence clinical studies in 2018. Commercial terms of the deal were not disclosed.

RON is a receptor tyrosine kinase and an overexpression of RON leads to increased tumor metastasis. Consequently, RON activation in tumor cells promotes aggressive disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK